RT Journal Article
SR Electronic
T1 Development and validation of direct RT-LAMP for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20075747
DO 10.1101/2020.04.29.20075747
A1 Mohon, Abu Naser
A1 Hundt, Jana
A1 van Marle, Guido
A1 Pabbaraju, Kanti
A1 Berenger, Byron
A1 Griener, Thomas
A1 Lisboa, Luiz
A1 Church, Deirdre
A1 Czub, Markus
A1 Greninger, Alexander
A1 Jerome, Keith
A1 Doolan, Cody
A1 Pillai, Dylan R.
YR 2020
UL http://medrxiv.org/content/early/2020/05/07/2020.04.29.20075747.abstract
AB We have developed a reverse-transcriptase loop mediated amplification (RT-LAMP) method targeting genes encoding the Spike (S) protein and RNA-dependent RNA polymerase (RdRP) of SARS-CoV-2. The LAMP assay achieves comparable limit of detection as commonly used RT-PCR protocols based on artificial targets, recombinant Sindbis virus, and clinical samples. Clinical validation of single-target (S gene) LAMP (N=120) showed a positive percent agreement (PPA) of 41/42 (97.62%) and negative percent agreement (NPA) of 77/78 (98.72%) compared to reference RT-PCR. Dual-target RT-LAMP (S and RdRP gene) achieved a PPA of 44/48 (91.97%) and NPA 72/72 (100%) when including discrepant samples. The assay can be performed without a formal extraction procedure, with lyophilized reagents which do need cold chain, and is amenable to point-of-care application with visual detection.Competing Interest StatementPatents related to LAMP technology (ANM, DRP)Funding StatementFunding for this study was obtained from the Canadian Institutes for Health Research (NFRFR-2019-00015, DRP) and Genome Canada (DRP), and from the M.J. Murdock Charitable Trust (KRJ).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon reasonable request from the corresponding author.